Bacterial Conjunctivitis Drugs Market – Global Forecasts upto 2024
- June, 2018
- Domain: Healthcare - Pharmaceuticals
- Get Free 10% Customization in this Report
Overview: Bacterial conjunctivitis is a contagious eye infection in which the conjunctiva of one or both the eyes are infected by bacteria such as Staphylococci, Gonococci, Chlamydia, and Streptococci. The infection caused by Chlamydia trachomatis and Neisseria gonorrhea species are extremely severe. However, there are many antibiotics that help in curing these conditions, thus ensuring quicker clearance of the indications of infection. Healio reported that nearly 5 million bacterial conjunctivitis cases are registered every year. There are many antibiotics currently used for the treatment, which include Besivance, Zymaxid, Maxitrol, and AzaSite. These antibiotics can be administered via oral, transdermal, and otic.
Although, most of the bacterial conjunctivitis are self-limiting, yet topical antibiotics are suggested to cut the duration of the disease and avoid the spreading of infection. A wide range of antibiotics are generally used as a primary treatment option for bacterial conjunctivitis. Topical antibiotics are suggested to deliver the highest dose of the drug straight to the infection site, more than what is usually achieved by oral and other routes. Consequently, the broad spectrum of antibiotic of a single drug is improved.
Market Analysis: The “Global Bacterial Conjunctivitis Drugs Market” is estimated to witness a CAGR of ‑2.1% during the forecast period 2018–2024. The bacterial conjunctivitis drugs market is analyzed based on two segments – drug class and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America accounts for the largest share of the bacterial conjunctivitis market, followed by Europe, Asia Pacific, and Rest of the World. More than 40% of the market is occupied by North America, with the US being the major contributor to the market growth.
Drug Class Analysis: Based on drug classes, the market is segmented into fluoroquinolones, aminoglycosides, macrolides, and others. Fluoroquinolones have a dominant market share for bacterial conjunctivitis. However, this drug class is likely to reduce its market share by 7.2% by the end of 2024 due to weak research pipeline. The highest growth rate is witnessed by aminoglycosides, followed by macrolides. However, the loss of patent of blockbuster drugs, such as Moxeza, Besivance, Vigamox, and Zymaxid, has hampered the growth of the market.
Key Players: The major players in the market include Novartis, Valeant Pharmaceuticals International, Teva Pharmaceuticals, and Akron Inc. Perrigo Corporation, Bayer AG, Pfizer, Daiichi Sankyo Inc., Merck & Co., and F. Hoffmann-La Roche are few of the prominent drugs manufacturers in the market.
Competitive Analysis: Many blockbuster drugs are likely to lose their patents in the market, which in turn, has increased the advent of generic drugs with similar efficacy and less cost. Novartis AG is one of the global leaders in the bacterial conjunctivitis market. Vigamox and Moxeza are the key products of the company, which are expected to lose their patents by 2020. This patent expiry is expected to show a negative impact on the company revenue and its market position. Other strategies used by the market players are acquisitions. For instance, in 2015, Shire Plc acquired Foresight Biotherapeutics for a value of $300 million. This acquisition added experimental eye drop FST-100 into the Shire Plc’s portfolio to treat both viral and bacterial conjunctivitis.
Benefits: The report provides complete details about the usage and adoption rate of bacterial conjunctivitis drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
1 Industry Outlook
1.1 Industry Overview
1.1.1 Global Driver for Pharmaceutical Demand:
1.1.2 Pharmaceutical Spending Region Wise
1.1.3 R&D Pipeline in Pharmaceutical Industry
1.1.4 Top Pharma Drugs by Sales in 2017 ($Million)
1.2 Industry Trends
1.3 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Trends of Bacterial Conjunctivitis Drugs Market
3.4 Related Markets
3.4.1 Contact Lenses
188.8.131.52 Trends of contact lens market
3.4.2 Active Pharmaceutical Ingredients (APIs)
3.4.3 Over the Counter Drugs (OTC)
4 Market Outline
4.1 Market Segmentation
4.2 Porter 5 (Five) Forces
4.3 PEST Analysis
5 Market Characteristics
5.1 Market Dynamics of Bacterial Conjunctivitis Drugs Market
184.108.40.206 Increasing awareness among patient population about pink eye disease
220.127.116.11 Rising prevalence of bacterial conjunctivitis
18.104.22.168 Increasing number of molecules in the clinical trials
22.214.171.124 Expiry of patents of blockbuster drugs
126.96.36.199 Complex drug development process
5.1.4 DRO – Impact Analysis
5.1.5 Key Stakeholders
6 Drug Class: Market Size and Analysis
7 Regions: Market Size and Analysis
7.2 North America
7.5 Rest of the World
8 Competitive Landscape
9 Vendor Profiles
9.1 Novartis AG
9.1.2 Business Units
9.1.3 Geographic Presence
9.1.4 Business Focus
9.1.5 SWOT Analysis
9.1.6 Business Strategy
9.2 Valeant Pharmaceuticals International Inc. (Bausch Health)
9.2.2 Business Units
9.2.3 Geographic Presence
9.2.4 Business Focus
9.2.5 SWOT Analysis
9.2.6 Business Strategy
9.3 Teva Pharmaceutical Industries Ltd.
9.3.2 Business Units
9.3.3 Geographic Presence
9.3.4 Business Focus
9.3.5 SWOT Analysis
9.3.6 Business Strategy
9.4 Akorn Inc.
9.4.2 Business Focus
9.4.3 SWOT Analysis
9.4.4 Business Strategy
10 Companies to Watch For
10.1 Santen Pharmaceutical Co., Ltd.
10.2 Perrigo Company plc
10.3 Merck & Co.
10.4 Pfizer Inc.,
10.5 Daiichi Sankyo, Inc.
10.6 Bayer AG
10.7 F. Hoffmann-La Roche
TABLE 1 PATENT EXPIRATION OF RESPIRATORY DRUGS 28
TABLE 2 BACTERIAL CONJUNCTIVITES DRUGS MARKET REVENUE BY DRUG CLASS, 2017–2024 ($MILLION) 32
TABLE 3 BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION) 37
TABLE 4 POPULATION LIVING IN ENDEMIC AREAS OF TRACHOMA BY COUNTRY 42
TABLE 5 NOVARTIS AG: OFFERINGS 46
TABLE 6 NOVARTIS AG: RECENT DEVELOPMENTS 47
TABLE 7 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: OFFERINGS 54
TABLE 8 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: RECENT DEVELOPMENTS 54
TABLE 9 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERINGS 59
TABLE 10 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS 59
TABLE 11 AKORN INC: OFFERINGS 64
TABLE 12 AKRON INC.: RECENT DEVELOPMENTS 65
TABLE 13 SANTEN PHARMACEUTICAL CO., LTD.: OVERVIEW 69
TABLE 14 SANTEN PHARMACEUTICAL CO., LTD.: RECENT DEVELOPMENTS 69
TABLE 15 PERRIGO COMPANY PLC: OVERVIEW 70
TABLE 16 PERRIGO COMPANY PLC: RECENT DEVELOPMENTS 70
TABLE 17 MERCK & CO: OVERVIEW 71
TABLE 18 MERCK & CO: RECENT DEVELOPMENTS 71
TABLE 19 PFIZER: RECENT DEVELOPMENTS 73
TABLE 20 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS 74
TABLE 21 BAYER AG: OVERVIEW 75
TABLE 22 BAYER AG: RECENT DEVELOPMENTS 75
TABLE 23 F. HOFFMANN-LA ROCHE: OVERVIEW 76
TABLE 24 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 76
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
Market related information is congregated from both primary and secondary sources.
Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.